NEW YORK, Nov. 16, 2021 /PRNewswire/ -- Mind Medicine
(MindMed) Inc. (NASDAQ: MNMD; NEO: MMED; DE: MMQ; the "Company"), a
leading biotech company developing psychedelic-inspired therapies,
is pleased to announce it has launched recruitment for a randomized
placebo-controlled study evaluating the effects of daytime and
evening administration of repeated low doses of LSD (the "LSD
Study").
Researchers will use digital measurement devices and software to
measure the effects of microdoses of LSD on neuroplasticity markers
such as BDNF plasma levels, as well as on various sleep measures,
mood, cognitive performance, regulation of emotions, quality of
life, and immune system response. The study will be conducted by
Dr. Kim Kuypers of Maastricht University, a leading global authority
on the use of low dose psychedelics.
"Research into the practice of taking repeated low doses of
psychedelics starts with the basics, looking at whether there is a
time of day that influences the impact of these treatments," said
Dr. Kuypers. "We are investigating whether the repeated intake of
lower doses could lead to realignment of patterns of thinking that
would enable individuals to access levels of self-awareness that
can provide an enriched experience of life."
"Increasingly, claims are being made about so-called
'microdosing' of psychedelics regarding the potential to impact
mental and physical well-being, cognition, memory, and specific
aspects such as creativity and productivity," said Dr. Miri
Halperin Wernli, MindMed's Executive
President. "However, scientific evidence to support or even fully
explore the safety and benefits claimed has been lacking.
With our innovative study design, integrating digital medicine
measurement techniques with more traditional self-reporting and
cognitive tasks, our goal is to provide insight on key parameters
that may impact and explain the mechanisms behind low-dose
treatments. These parameters include diurnal versus nocturnal
differences and possible cumulative effects due to repeated
administration. This regimen could provide new tools to deal with
various pathologies, helping to unblock pathological ways of
thinking by shifting an individual's perspective, catalyzing
insights and ultimately changing problematic and habitual mindsets
and behaviours."
About MindMed
MindMed is a clinical-stage psychedelic medicine biotech company
that seeks to discover, develop and deploy psychedelic-inspired
medicines and therapies to address addiction and mental illness.
The Company is assembling a compelling drug development pipeline of
innovative treatments based on psychedelic substances including
psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The
MindMed executive team brings extensive biopharmaceutical
experience to MindMed's approach to developing the next generation
of psychedelic-inspired medicines and therapies.
MindMed trades on the NASDAQ under the symbol MNMD and on the
Canadian NEO Exchange under the
symbol MMED. MindMed is also traded in Germany under the symbol MMQ.
Forward-Looking Statements
Certain statements in this news release related to the Company
constitute "forward-looking information" within the meaning of
applicable securities laws and are prospective in nature.
Forward-looking information is not based on historical facts, but
rather on current expectations and projections about future events
and are therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. These
statements generally can be identified by the use of
forward-looking words such as "will", "may", "should", "could",
"intend", "estimate", "plan", "anticipate", "expect", "believe",
"potential" or "continue", or the negative thereof or similar
variations. Forward-looking information in this news release
include, but are not limited to, statements regarding the potential
safety and benefits of 'microdosing' of psychedelics and the
ability of the Company to complete and achieve the goals of the LSD
study. Although the Company believes that the expectations
reflected in such forward-looking information are reasonable, such
information involves risks and uncertainties, and undue reliance
should not be placed on such information, as unknown or
unpredictable factors could have material adverse effects on future
results, performance or achievements of the Company. There are
numerous risks and uncertainties that could cause actual results
and the Company's plans and objectives to differ materially from
those expressed in the forward-looking information, including
history of negative cash flows; limited operating history;
incurrence of future losses; availability of additional capital;
lack of product revenue; compliance with laws and regulations;
difficulty associated with research and development; risks
associated with clinical trials or studies; heightened regulatory
scrutiny; early stage product development; clinical trial risks;
regulatory approval processes; novelty of the psychedelic inspired
medicines industry; as well as those risk factors discussed or
referred to herein and the risks described under the headings "Risk
Factors" in the Company's filings with the securities regulatory
authorities in all provinces and territories of Canada which are available under the
Company's profile on SEDAR at www.sedar.com and with the U.S.
Securities and Exchange Commission on EDGAR at www.sec.gov.
Should one or more of these risks or uncertainties materialize, or
should assumptions underlying the forward-looking information prove
incorrect, actual results and future events could differ materially
from those anticipated in such information. Although the Company
has attempted to identify important risks, uncertainties and
factors that could cause actual results to differ materially, there
may be others that cause results not to be as anticipated,
estimated or intended. These and all subsequent written and oral
forward-looking information are based on estimates and opinions of
management on the dates they are made and are expressly qualified
in their entirety by this notice. Except as required by law, the
Company does not intend and does not assume any obligation to
update this forward-looking information.
Media Contact: mindmed@150bond.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mindmed-launches-study-of-low-dose-lsd-effects-on-sleep-and-cognitive-measures-301425200.html
SOURCE Mind Medicine (MindMed) Inc.